Literature DB >> 6269935

Timolol treatment in the irritable bowel syndrome.

J F Fielding.   

Abstract

The overall effect of the beta-blocker timolol maleate was not significantly different from placebo in patients with the irritable bowel syndrome on a high fibre diet. However, all 3 symptom-free patients were on timolol maleate. If beta-blockers have a major role to play in the treatment of the irritable bowel syndrome it must be through a central rather than a peripheral effect.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6269935     DOI: 10.1159/000198627

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  8 in total

1.  Lack of effect of cimetidine in the irritable colon syndrome.

Authors:  F Pidgeon; M Craig; J F Fielding
Journal:  Ir J Med Sci       Date:  1985-01       Impact factor: 1.568

Review 2.  The irritable bowel.

Authors:  W G Thompson
Journal:  Gut       Date:  1984-03       Impact factor: 23.059

3.  beta-Adrenoceptor blockers and colonic motility.

Authors:  J F Fielding
Journal:  Dig Dis Sci       Date:  1984-09       Impact factor: 3.199

4.  Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial.

Authors:  G Dobrilla; B P Imbimbo; L Piazzi; G Bensi
Journal:  Gut       Date:  1990-03       Impact factor: 23.059

5.  The non-effect of pirenzepine in dietary resistant irritable bowel syndrome.

Authors:  J Gilvarry; A Kenny; J F Fielding
Journal:  Ir J Med Sci       Date:  1989-10       Impact factor: 1.568

Review 6.  Evaluation of drug treatment in irritable bowel syndrome.

Authors:  Nicholas J Talley
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

7.  Effects of beta-adrenoceptor blocking drugs on human sigmoid colonic motility.

Authors:  H Abrahamsson; E Lyrenäs; G Dotevall
Journal:  Dig Dis Sci       Date:  1983-07       Impact factor: 3.199

8.  Genetic variation in the beta-2 adrenergic receptor (ADRB2) predicts functional gastrointestinal diagnoses and poorer health-related quality of life.

Authors:  V M Kushnir; B Cassell; C P Gyawali; R D Newberry; P Kibe; B D Nix; A Sabzpoushan; N D Kanuri; G S Sayuk
Journal:  Aliment Pharmacol Ther       Date:  2013-06-20       Impact factor: 8.171

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.